摘要
目的比较奥拉西坦与吡拉西坦治疗轻、中度阿尔茨海默病的疗效和安全性。方法将70例轻、中度阿尔茨海默病病人随机分入奥拉西坦治疗组(35例)与吡拉西坦对照组(35例)进行治疗,通过MMSE量表、Blessed-Roth量表对两组疗效进行评价。结果奥拉西坦治疗组治疗前后的MMSE、Blessed-Roth评分值差异有统计学意义(P<0.01);吡拉西坦治疗组治疗前后评分值差异也有统计学意义(P<0.05)。两组间治疗前后MMSE和Blessed-Roth评分的差值比较差异有统计学意义(P<0.05)。奥拉西坦治疗组与吡拉西坦治疗组总有效率分别为63%、34%,其疗效差异具有统计学意义(P<0.01)。结论奥拉西坦与吡拉西坦治疗轻、中度阿尔茨海默病病人均有效,但前者疗效优于后者。
Objective To compare the therapeutic effects and safety of oxiraeetam and piraeetam in the treatment of mild or medium Alzheimer＇ s disease. Methods A total of 70 patients with mild or medium Alzheimer＇ s disease were randomized into oxiraeetam group （n=35） and piraeetarn group （n=35）. MMSE and Blessed-Roth scales were used to evaluate the therapeutic effects. Results Except for daily life ability, all other indexes improved after treatment in the patients of both groups, compared with the Pre-treatment condition. The differences were statistically significant （P〈0.01 or P〈0.05）. Compared with piracetam group, the difference in MMSE and Blessed-Roth values was more significant in oxiraeetam group （P〈0.05）. The overall curative rate of oxiracetam group was higher than that of piracetam group （63 % vs 34%, P〈0.01）. Conclusions Both oxiraeetam and piracetam are effective in the treatment of mild and medium forms of Alzheimer＇ s disease, and the former is even hetter thau the latter.
出处
《老年医学与保健》
CAS
2007年第5期307-309,共3页
Geriatrics & Health Care
